Hwang Jung Ho, Park Se Yong, Kang Ju-Hee, Jung Hyun Jin, Park Jiwon, Maeng Han-Joo, Choi Min-Koo, Song Ha Suk, Song Im-Sook, Oh Seung Hyun
College of Pharmacy, Gachon University, Incheon, South Korea.
College of Veterinary Medicine, Seoul National University, Seoul, South Korea.
J Ginseng Res. 2025 Jul;49(4):438-450. doi: 10.1016/j.jgr.2025.03.010. Epub 2025 Apr 4.
Despite the efficacy of anticancer drugs, patients frequently experience relapse, metastasis, and resistance. A promising therapeutic approach not only targets cancer cell growth but also modulates cancer-associated fibroblasts, which support malignancies. Compound K (CK), a metabolite derived from red ginseng, has demonstrated anticancer properties. Recently, we developed a CK-enriched red ginseng extract (CKP) and explored its potential to suppress lung cancer by inhibiting cancer cell proliferation and inactivating fibroblasts.
To evaluate the efficacy of CKP in inhibiting lung cancer cell proliferation, MTT and colony formation assays were performed. The apoptotic effects of CKP on lung cancer cells were assessed using Western blot and flow cytometry. Furthermore, the ability of CKP to inhibit TGF β1-induced migration of cancer cells was investigated through Western blot, RT-PCR, and a wound healing assay. Additionally, the impact of CKP on lung fibroblast inactivation was examined via Western blot and RT-PCR analysis. For experiments, a xenograft model was utilized, incorporating a combination of lung cancer cells and lung fibroblasts in xenografts.
CKP significantly reduced the proliferation and invasiveness of TGF-β1-stimulated A549 cells, demonstrating its potential to inactivate lung fibroblasts. Additionally, CKP inhibited the secretion of cytokines, such as interleukin-6, interleukin-8, and TGF-β1, by activated fibroblasts. , CKP markedly inhibited tumor growth in the xenograft model.
In conclusion, CKP effectively induced apoptosis in lung cancer cells, suppressed metastasis, and inactivated fibroblasts, thereby preventing cancer invasion and reducing extracellular matrix production, highlighting its potential as a novel anticancer agent.
尽管抗癌药物具有疗效,但患者经常出现复发、转移和耐药性。一种有前景的治疗方法不仅要针对癌细胞的生长,还要调节支持恶性肿瘤的癌症相关成纤维细胞。化合物K(CK)是红参衍生的一种代谢产物,已显示出抗癌特性。最近,我们开发了一种富含CK的红参提取物(CKP),并探讨了其通过抑制癌细胞增殖和使成纤维细胞失活来抑制肺癌的潜力。
为了评估CKP抑制肺癌细胞增殖的疗效,进行了MTT和集落形成试验。使用蛋白质免疫印迹法和流式细胞术评估CKP对肺癌细胞的凋亡作用。此外,通过蛋白质免疫印迹法、逆转录-聚合酶链反应(RT-PCR)和伤口愈合试验研究了CKP抑制转化生长因子β1(TGF-β1)诱导的癌细胞迁移的能力。另外,通过蛋白质免疫印迹法和RT-PCR分析检查了CKP对肺成纤维细胞失活的影响。对于实验,使用了异种移植模型,在异种移植中结合了肺癌细胞和肺成纤维细胞。
CKP显著降低了TGF-β1刺激的A549细胞的增殖和侵袭性,表明其具有使肺成纤维细胞失活的潜力。此外,CKP抑制了活化的成纤维细胞分泌细胞因子,如白细胞介素-6、白细胞介素-8和TGF-β1。此外,CKP在异种移植模型中显著抑制了肿瘤生长。
总之,CKP有效地诱导肺癌细胞凋亡,抑制转移,并使成纤维细胞失活,从而防止癌症侵袭并减少细胞外基质的产生,突出了其作为新型抗癌剂的潜力。